CS/BSE/NSE/PR/20162017

June29,2016

To
TheManager
ListingDepartment
NationalStockExchangeofIndiaLimited
ExchangePlaza,BandraKurlaComplex
Bandra(E),Mumbai400051

StockCode:SUVENEQ

To
TheGeneralManager
DepartmentofCorporateServices
BSELimited
25thFloor,P.J.Towers,
DalalStreet,Mumbai400001

StockCode:530239

DearSir/Madam,

Sub:PressRelease

With reference to above subject, please find enclosed Press Release of our
companytitledSuvenLifeSciencessecuresthree(3)ProductPatentsinEurope
andEurasia

Thisisforyourinformationandrecords

ThankingYou,
Yoursfaithfully,
ForSuvenLifeSciencesLimited

K.HanumanthaRao
CompanySecretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C I N : L 2 41 10 T G 1 9 8 9 P L C 00 97 1 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

NewsRelease

SuvenLifeSciencessecuresthree(3)ProductPatentsinEuropeandEurasia

HYDERABAD, INDIA (June 29, 2016) Suven Life Sciences Ltd (Suven) announces today that
thegrantofone(1)productpatentfromEurope(2507225)andtwo(2)productpatentsfrom
Eurasia (023293 and 023260) corresponding to the New Chemical Entities (NCEs) for the
treatmentofdisordersassociatedwithNeurodegenerativediseasesandthesePatentsarevalid
through2029,2030and2031respectively.

The granted claims of the patents are from the mechanism of action include the class of
selective 5HT4 compounds, Alpha4Beta2 and H3Inverse agonist compounds and are being
developed as therapeutic agents and are useful in the treatment of cognitive impairment
associated with neurodegenerative disorders like Alzheimers disease, Attention deficient
hyperactivity disorder (ADHD), Huntingtons disease, Major Depressive disorder (MDD),
ParkinsonandSchizophrenia.

Withthesenewpatents,Suvenhasatotaloftwentyone(21)grantedpatentsfromEuropeand
Nineteen (19) granted patents from Eurasia. These granted patents are exclusive intellectual
property of Suven and are achieved through the internal discovery research efforts. Products
out of these inventions may be outlicensed at various phases of clinical development like at
PhaseIorPhaseII.

We are very pleased by the grant of these patents to Suven for our pipeline of molecules in
CNSarenathatarebeingdevelopedforcognitivedisorderswithhighunmetmedicalneedwith
hugemarketpotentialgloballysaysVenkatJasti,CEOofSuven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and

commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2
undergoing candidate SUVN502, Phase 1 completed candidate SUVNG3031 and Phase 1
undergoing candidate SUVND4010 for Alzheimers disease and Schizophrenia. In addition to
that the Company has ten (10) internallydiscovered therapeutic drug candidates currently in
preclinical stage of development targeting conditions such as ADHD, dementia, depression,
Huntingtons disease, Major Depressive Disorder (MDD), Parkinsons disease, pain and
Schizophrenia.

FormoreinformationpleasevisitourWebsiteathttp://www.suven.com

RiskStatement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forwardlooking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forwardlooking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retentionofkeypersonnel,technologicaladvancesandcontinuedsuccessingrowthofsalesthatmaymake
our products/services offerings less competitive; Suvenmaynotundertake to update anyforwardlooking
statementsthatmaybemadefromtimetotime.

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th FloorRoad No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C I N : L 24 11 0T G 1 9 8 9P L C 0 0 97 13
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com